Patents Examined by Emily Bernhardt
  • Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders
    Patent number: 10806723
    Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 20, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • Heterocyclic amide compound
    Patent number: 10800754
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 13, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Masato Yoshida, Shinichi Imamura
  • Polymorphic forms of Afatinib free base and Afatinib dimaleate
    Patent number: 10800763
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 13, 2020
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
  • Polymorphic forms of VENCLEXTA
    Patent number: 10800777
    Abstract: The present disclosure relates to crystalline forms of venetoclax and process for their preparation. The present disclosure also relates to process for preparation of amorphous venetoclax.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 13, 2020
    Assignee: Mylan Laboratories Limited
    Inventors: Ramakoteswara Rao Jetti, Hemant Malhari Mande, Anjaneyaraju Indukuri, Narasimha Murthy Pilli, Rajesh Joshi, Anil Kumar Tripathi, Chandrakant Chaudhri, Kiran Pokharkar, Nagaraju Gottumukkala
  • Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors
    Patent number: 10800785
    Abstract: Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: October 13, 2020
    Assignees: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Weipeng Zhang, Zhifang Chen, Ling Chen, Xianlong Wang, Zhifu Li, Rui Tan, Lijun Yang, Haohan Tan, Bin Liu, Kai Ran, Zongyao Zou, Min Lin, Jing Sun, Weibo Wang
  • Compounds which are used in the preparation of the compound of formula (II)
    Patent number: 10800762
    Abstract: This invention relates to compounds which are used in the preparation of the compound of formula (II).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: October 13, 2020
    Assignee: PULMOCIDE LIMITED
    Inventors: Mihiro Sunose, Thomas Christopher Colley, Kazuhiro Ito, Garth Rapeport, Peter Strong
  • Oxoisoquinoline derivatives
    Patent number: 10793575
    Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 6, 2020
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Wataru Kawahata, Takao Kiyoi, Takayuki Irie, Tokiko Asami, Masaaki Sawa, Shigeki Kashimoto
  • PH responsive fluorescent compound, composition for detecting mitophagy using same, and method for detecting mitophagy within cells
    Patent number: 10787473
    Abstract: Disclosed is a pH-responsive fluorescent compound, represented by the general formula, which is a novel pH-responsive fluorescent compound capable of being specifically localized in mitochondria within cells, which exhibits strong fluorescence under weakly acidic pH environments in lysosomes, and which is not readily subject to interference from autofluorescence and background fluorescence due to other fluorescent substances within cells. Also disclosed are a composition for detecting mitophagy using the pH-responsive fluorescent compound, and a method for detecting mitophagy within cells. In the general formula, L represents a linker, X represents a pharmaceutically acceptable anion, and Y represents a reactive group that may react with a functional group on a mitochondrial protein to form a covalent bond.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: September 29, 2020
    Assignee: DOJINDO LABORATORIES
    Inventors: Hidefumi Iwashita, Ryo Sakamoto, Munetaka Ishiyama
  • Organic compound, composition, and organic optoelectronic diode
    Patent number: 10784447
    Abstract: The present invention relates to: an organic compound represented by Chemical Formula 1; a composition for an organic optoelectronic diode containing the organic compound; and an organic optoelectronic diode to which the organic compound or the composition is applied. In Chemical Formula 1, Z, R1 to R11, and n1 to n4 are the same as those defined in the specification.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 22, 2020
    Assignee: SAMSUNG SDI CO., LTD.
    Inventors: Sujin Han, Dong Min Kang, Soohyun Min, Eun Sun Yu, Byoungkwan Lee, Hanill Lee, Sung-Hyun Jung, Ho Kuk Jung
  • Kinase inhibitor against wild-type and mutant EGFR
    Patent number: 10781214
    Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: September 22, 2020
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD.
    Inventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Hong Wu, Kailin Yu, Chen Hu, Wenchao Wang, Cheng Chen, Fengming Zou, Ziping Qi, Li Wang, Beilei Wang
  • Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
    Patent number: 10772884
    Abstract: The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: September 15, 2020
    Assignees: Alzprotect, Universite De Lille 2 Droit Et Sante, INSERM (Institut National De La Sante Et De La Recherche)
    Inventors: Stéphane Burlet, Cécilia Estrella, Mathieu Barrier, Patricia Melnyk, Nicolas Sergeant, Luc Buee, Philippe Verwaerde
  • Triazoles for the treatment of demyelinating dieases
    Patent number: 10766869
    Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: September 8, 2020
    Assignee: VERTEX PHARMACEUTCALS INCORPORATED
    Inventors: Robert J. Davies, Jingrong Cao, Meghan Elise Cockerill, Philip Noel Collier, Elisabeth Doyle, James Daniel Frantz, Huai Gao, Brian Anthony Goldman, Ronald Lee Grey, Jr., Anne-Laure Grillot, Wenxin Gu, James A. Henderson, Raul Eduardo Krauss, Adrianne Lynn Kolpak, Yusheng Liao, Sanjay Shivayogi Magavi, David Messersmith, Albert Charles Pierce, Emanuele Perola, Elizabeth Jin-Sun Ryu, Joshua Syken, Jian Wang, Michael Paul DeNinno, Francois Maltais
  • [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
    Patent number: 10766905
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Fused hexacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10766906
    Abstract: Disclosed are substituted fused hexacyclic benzimidazole derivatives of Formula (I) wherein the variables A, B, D, X, M, Q, n, p, q, Z, E, R5, and R12 are defined herein. These compounds are potent modulators of human TNF? activity and of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Teresa De Haro Garcia, Michael Louis Robert Deligny, Jag Paul Heer, Helen Tracey Horsley, Sophie Jadot, Jean Keyaerts
  • 4-methylsulfonyl-substituted piperidine urea compounds
    Patent number: 10758525
    Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: September 1, 2020
    Assignee: MyoKardia, Inc.
    Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
  • Substituted guanidine derivatives
    Patent number: 10759781
    Abstract: The present invention provides a compound of general formula (I) (wherein, R1, X, p and q are as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 1, 2020
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Ken-ichi Komori, Akishi Ninomiya, Shigeru Ushiyama, Masaru Shinohara, Koji Ito, Tetsuo Kawaguchi, Yasunori Tokunaga, Hiroyoshi Kawada, Haruka Yamada, Yusuke Shiraishi, Masahiro Kojima, Masaaki Ito, Tomio Kimura
  • 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
    Patent number: 10758533
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: September 1, 2020
    Assignee: NOVARTIS AG
    Inventors: Atwood Kim Cheung, Donovan Noel Chin, Natalie Dales, Aleem Fazal, Timothy Brian Hurley, John Kerrigan, Gary O'Brien, Lei Shu, Robert Sun, Moo Je Sung
  • EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application
    Patent number: 10759782
    Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: September 1, 2020
    Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanhgai Hansoh Biomecial Co., Ltd.
    Inventors: Zhongke Chen, Fuping Liu, Lei Liu, Rudi Bao
  • HIV inhibitor compounds
    Patent number: 10752636
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: August 25, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Calcium channel agonists
    Patent number: 10752629
    Abstract: Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: August 25, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Stephen D. Meriney, Mary Liang